ARX424

ARX424 is a preclinical biologic candidate developed for the treatment of multiple sclerosis. It was created by Ambrx using its proprietary ReCODE (Reconstituting Chemically Orthogonal Directed Engineering) protein optimization technology, which enables the site-specific incorporation of non-natural amino acids to improve the pharmacological profile of protein therapeutics. In 2009, Ambrx partnered with Merck Serono (a division of Merck KGaA) for the worldwide development and commercialization of the candidate. The specific biological target of ARX424 has not been publicly disclosed, though the program leverages protein engineering to address the pathology of multiple sclerosis.